| Market Cap | 6.75M | P/E | - | EPS this Y | - | Ern Qtrly Grth | - |
| Income | -29.88M | Forward P/E | -0.28 | EPS next Y | - | 50D Avg Chg | -24.00% |
| Sales | 4.64M | PEG | - | EPS past 5Y | - | 200D Avg Chg | -72.00% |
| Dividend | N/A | Price/Book | 0.40 | EPS next 5Y | - | 52W High Chg | -93.00% |
| Recommedations | 1.70 | Quick Ratio | 5.22 | Shares Outstanding | 2.87M | 52W Low Chg | 21.00% |
| Insider Own | 1.21% | ROA | -80.20% | Shares Float | 2.70M | Beta | 0.08 |
| Inst Own | 13.08% | ROE | -157.29% | Shares Shorted/Prior | 189.60K/181.26K | Price | 2.35 |
| Gross Margin | - | Profit Margin | - | Avg. Volume | 325,650 | Target Price | 17.83 |
| Oper. Margin | -657.53% | Earnings Date | Nov 7 | Volume | 31,317 | Change | 2.17% |
Brickell Biotech, Inc., a clinical-stage pharmaceutical company, engages in the development of various prescription therapeutics for the treatment of autoimmune, inflammatory, and other debilitating diseases in the United States. The company develops sofpironium bromide, which has completed Phase III clinical trials for the treatment of primary axillary hyperhidrosis; BBI-02, an oral DYRK1A inhibitor for the treatment of autoimmune and inflammatory diseases; and BBI-10, a covalent stimulator of interferon genes inhibitor for the potential treatment of autoinflammatory and rare genetic diseases, as well as next-generation kinase inhibitors. It has license and collaboration agreements with Carna Biosciences, Inc., Voronoi Inc., Bodor Laboratories, Inc. and Dr. Nicholas S. Bodor, and AnGes, Inc. The company was founded in 2009 and is headquartered in Boulder, Colorado.